Baseline clinical characteristics.
| SSc, n = 78 | Non-SSc, n = 156 | P | |
|---|---|---|---|
| Age at diagnosis, yrs | 56.0 (± 15.6) | 56.1 (± 15.7) | 0.97 |
| Female sex | 71 (91) | 142 (91) | > 0.99 |
| Ethnicity | 0.24 | ||
| White | 68 (87) | 147 (94) | |
| African American | 2 (3) | 3 (2) | |
| Hispanic | 1 (1) | 2 (1) | |
| Asian | 5 (6) | 3 (2) | |
| Other/unknown | 2 (3) | 1 (1) | |
| Follow-up, yrs | 10.5 (4.0, 17.5) | 13.0 (6.7, 20.0) | – |
| BMI, kg/m2 | 26.5 (± 5.9) | 29.4 (± 7.6) | 0.004 |
| Obesity (BMI ≥ 30 kg/m2) | 15 (21) | 61 (39) | 0.008 |
| Smoking status | 0.54 | ||
| Current | 12 (16) | 30 (20) | |
| Former | 24 (31) | 38 (25) | |
| 2013 ACR/EULARa | 71 (91) | – | – |
| Prior diabetes | 2 (3) | 19 (12) | 0.02 |
| Prior hypertension | 30 (38) | 57 (37) | 0.77 |
| Prior hyperlipidemia | 27 (35) | 55 (35) | 0.92 |
| Prior CAD | 11 (14) | 17 (11) | 0.48 |
| Prior PH | 6 (8) | 1 (1) | 0.003 |
| Prior ILD | 7 (9) | – | – |
| Skin involvement | |||
| Limited cutaneous | 65 (83) | – | |
| Diffuse cutaneous | 11 (14) | – | |
| Sine scleroderma | 2 (3) | – | |
| SSc-specific antibodies, n/N (%) | 38/75 (51) | – | |
| Scl70+ | 7/35 (20) | – | |
| ACA+ | 29/35 (83) | – | |
| RNAPIII+ | 2/35 (6) | – | |
Values are expressed as mean (± SD) or median (25th percentile, 75th percentile) for continuous characteristics, and n (%) or n/N (%) for discrete characteristics.
↵aFulfilled 2013 ACR/EULAR classification criteria at baseline. ACA: anticentromere antibody; ACR/EULAR: American College of Rheumatology/European League Against Rheumatism; CAD: coronary artery disease; ILD: interstitial lung disease; PH: pulmonary hypertension; RNAPIII: RNA polymerase III; SSc: systemic sclerosis.